News
TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial
New York-headquartered biopharma company TG Therapeutics has revealed new data for its investigational therapy ublituximab, which demonstrated superiority over Sanofi’s Aubagio in patients with relapsing forms of multiple sclerosis (MS).